Insights and lessons from the ODYSSEY outcomes trial: which patients benefit most?

31 August 2019 (15:35 - 15:50)

Organised by:

About the speaker

Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

4 More presentations in this session

Presentation thumbnail

Introduction

Professor J. Chapman (Paris, FR)

Presentation thumbnail

Extending the evidence: what did the FOURIER trial learns us on managing high risk patients?

Professor M. Sabatine (Boston, US)

Presentation thumbnail

Targeting PCSK9: expanding knowledge and targeting new frontiers

Professor J. Kastelein (Amsterdam, NL)

Presentation thumbnail

Discussion

Professor J. Chapman (Paris, FR) Professor J. Kastelein (Amsterdam, NL)

Access the full session

Session thumbnail

PCSK9i, changing practice in cardiology: the emerging story

The Event

ESC Congress 2019

31 August 2019 15:35 CET

You may be interested in

Congress Presentation

Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events

31 August 2025

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

19 July 2023

Congress Presentation

Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study

27 August 2021

Webinar

LDL-C reduction postACS: strike early and strike strong

15 November 2021

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources